Latozinemab

Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research[1][2].

Product Specifications

CAS Number

[2376132-27-1]

Product Name Alternative

AL001

UNSPSC

12352203

Target

Neurotensin Receptor

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/latozinemab.html

Purity

96.03

Solubility

H2O

Smiles

[Latozinemab]

Molecular Weight

(146.28 kDa)

References & Citations

[1]Kurnellas M, et al. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023 Jun 15;21 (1) :387. |[2]Ek M, et al. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. Front Immunol. 2024 Aug 8;15:1437886.